US EditionTeragnosis, a New Strategy that Improves the Quality of Life in Advanced Tumors
Summary by Salud a Diario
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Currently Bellvitge, in collaboration with the Catalan Institute of Oncology, promotes an intense research activity with clinical trials with new generation radiopharmaceuticals to treat tumors such as prostate cancer, neuroendocrine cancer, glioblastoma, breast, lung and ovary, among others. The hospital is one of the centers that lead research in teragnosis in the state, both by number of trials and by variety of tumors treated. Specifically, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
